CervoMed Inc. (CRVO)
About CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $4.0M
- Net income
- -$27.0M
- Total assets
- $22.9M
- Market cap
- $24.6M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $24.6M
- Shares outstanding
- 10.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 18, 1996
CervoMed Inc. (CRVO) Stock Price
- Reported a net loss of $27.0M in FY2025.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CervoMed Inc..
Write a review
News about CervoMed Inc.
News & sentiment via Polygon.io
CervoMed Inc.: frequently asked questions
Is CervoMed Inc. an American company?
CervoMed Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is CervoMed Inc. headquartered?
CervoMed Inc. is headquartered in Boston, Massachusetts, United States.
Is CervoMed Inc. publicly traded?
Yes — CervoMed Inc. is a publicly traded company. Its stock trades under the ticker symbol CRVO on the NASDAQ.
What does CervoMed Inc. do?
CervoMed Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
